Objective: To obtain preliminary data on the short-and intermediateterm effects of battlefield acupuncture (BFA) on self-reported pain intensity in a relatively large cohort of veterans to assess whether a more comprehensive clinical trial evaluation is warranted.
O pioid prescribing for pain treatment has increased markedly in recent decades, 1 with dramatic, unintended consequences. For example, the mortality rate caused by prescription-opioid use increased fourfold between 2000 and 2014. 2 Dispensing of opioids has become so routine that even after a nonfatal overdose, 91% of patients continue to be prescribed these medications, with a reported 7% rate of second overdose. 3 It is widely believed that increased opioid prescribing is not only associated with elevated risk of overdose in patients using these medications as directed but also responsible for their pervasive nonmedical use and the epidemic of heroin abuse, a readily available and cheaper alternative. 2 Nonopioids prescribed for pain relief, such as nonsteroidal anti-inflammatory drugs and acetaminophen, also can cause adverse effects. 4 Integrative care has been suggested as a potentially safer alternative to opioids in the treatment of acute and chronic pain, [5] [6] [7] [8] and acupuncture in particular has been shown to be effective. 9 Battlefield acupuncture (BFA), a safe, inexpensive, and easily learned subset of auricular acupuncture 4, 7, [10] [11] [12] introduced by Niemtzow in 2001, 13 has been proposed to treat a variety of painful disorders in active military members and veterans, and is being promoted by the US Department of Defense, the US Department of Veterans Affairs (VA) and the US Department of Health and Human Services. 4, 10, 12, 14, 15 Recent work, however, has suggested that the evidence for using BFA is meager. 4, 14, [16] [17] [18] In addition, although there have been reports demonstrating the efficacy of BFA treatment, 12, 14, 16, 17, 19, 20 little is known regarding its durability. 17 For example, the study by Federman et al 21 was restricted to 7 days. Moreover, in most BFA studies, especially case series, the sample sizes have been small, 7, 8, 19, 20 thereby limiting support for this practice. 16 There is a need, therefore, for longer-term studies with larger sample sizes to be performed before BFA can be endorsed widely. 16 Another factor that has not been evaluated is how to efficiently incorporate BFA into a busy primary care practice. Because shared medical appointments (SMAs), also known as group visits, have been shown to be helpful in chronic disease management and may decrease healthcare utilization, 22 we developed an SMA for BFA within the context of a VA primary care practice. 21 In a pilot study with a moderately sized group of veterans, we successfully implemented and demonstrated the efficacy of SMA to offer BFA. 21 Although of relatively short duration, results of the study were encouraging: Veterans receiving BFA continued to experience diminished pain 7 days after treatment. Here, we sought to gain preliminary knowledge of the durability
Key Points
• Battlefield acupuncture (BFA) is highly efficacious in reducing short-and intermediate-term pain relief.
• BFA is well tolerated.
• Group visits are an efficient and effective way to provide BFA to patients who are interested in this modality.
of treatment to ascertain whether the technique warrants a more comprehensive, long-term clinical trial evaluation. We therefore expanded the pilot study to a longer duration of 30 days and offered BFA to a much larger pool of veterans. A secondary goal was to use the results of this quick, preliminary study to inform the design of future BFA research and treatment programs offered to patients with pain issues.
Methods

BFA Training
This study, conducted between March 2016 and December 2016, was reviewed by the VA Connecticut institutional review board and given a waiver. One of the authors (D.G.F.) underwent 4 hours of training in BFA by a fully trained and certified medical acupuncturist (also trained in BFA) as part of a VA continuing medical education program called the Pain Mini-Residency, a 3-day symposium aimed at pharmacologic and nonpharmacologic treatment of pain. The author performed six procedures under supervision of the trainer and was fully credentialed at VA Connecticut by the Professional Standards and Boards Subcommittee to perform BFA. During the next month, the author performed 26 additional procedures on veterans in his primary care practice.
Intervention Design
To expand the availability of the service and minimize the impact on access to routine care, we created a 90-minute SMA solely for BFA. Patients were recruited through a large informational poster in the primary care clinic waiting area that explained BFA and invited interested veterans to ask their provider or nurse for more information, including how to participate. In addition, e-mails were sent to all 36 primary care providers at the West Haven VA Medical Center, informing them that an SMA was available to patients interested in BFA for chronic pain. A separate 90-minute group clinic was created within the VA's software package, capable of accommodating 8 to 12 patients.
Treatment Delivery and Follow-Up
The first 30 minutes of the group appointment consisted of an informational session describing BFA, including the potential benefits, risks, and aftercare. It was made clear to patients that their pain issues must be thoroughly assessed by their primary care provider or other physicians for BFA treatment eligibility. Patients willing to undergo the procedure signed an electronic informed consent document. They were asked to avoid initiating other new therapies, if possible, for the 30-day period after BFA treatment. Each patient's baseline pretreatment self-reported pain level was recorded using the Defense and Veterans Pain Rating Scale, with a pain score of 1 to 10-1 being "hardly notice pain" and 10 being "as bad as it could be, nothing else matters." 23, 24 The BFA treatment consisted of first cleansing both ears with an alcohol swab and then inserting Aiguille Semi-permanente Original Gold needles (ASP Gold 200, Sedatelec, Irigny, France 25 ) sequentially to five traditional acupuncture points in each ear. 21 These tiny, sterile, disposable, gold-plated, nickel-free stainless steel needles housed in a plastic injector are semipermanent, intended for one-time use only. 25 Pain scores were obtained after each needle insertion. Patients were contacted by telephone on posttreatment days 1, 7, and 30, and their self-reported pain scores were collected.
Statistical Analysis
Descriptive statistics included means and standard deviations for patient age and frequencies for patient sex and race. Because the majority of the patient population was white, all of the other races were combined into a single, nonwhite category. Median pain scores and interquartile ranges were obtained at baseline (ie, pretreatment) and on posttreatment days 0, 1, 7, and 30. Mean pain scores and standard deviations were also computed at these time points. To illustrate graphically the temporal evolution of post-BFA pain levels, we generated pain score distributions at baseline and each posttreatment time point. To understand and evaluate the effectiveness of treatment on pain at a more granular level, we calculated for each baseline pain score and posttreatment time point the number and proportion of patients with decreased, unchanged, and increased pain relative to baseline together with the median decreases and increases in pain scores, as well as the overall mean pain score change from baseline. Given the nonrandomized, nonblinded nature of this preliminary, exploratory study that investigated the merit of a more comprehensive trial and for which we did not collect any other data, we did not consider more formal analysis to be appropriate. We used the Wilcoxon signed rank test to compare the pain score distributions at baseline with each of the four posttreatment time points. All of the statistical calculations were performed using 
Results
A total of 120 patients agreed to participate and attended the group BFA clinic. One patient could not complete treatment because of nausea and seven patients were dropped from the analysis, two because of a lack of follow-up pain scores and five because they did not want to be contacted. For the remaining 112 patients, the demographics and the baseline (ie, pretreatment) and posttreatment pain scores are given in Table 1 . The Figure shows how the pain score distribution evolved over time, from baseline to posttreatment day 30. For each baseline pain score, we report in Table 2 how the pain level changed with time.
The mean age was 64.7 years (range 29-91 years); 92.9% were men and 86.6% were white (Table 1) . At baseline, the Table 2 Table 2 ) of patients experienced considerable pain, with scores ≥5, indicating moderate to severe pain. 23, 24 The mode was 8 (Fig.) , reflecting severe pain ("awful, hard to do anything" 23, 24 ). The median and mean scores were 7 and 6.8 (Table 1) . Immediately after treatment, the pain score distribution displayed a significant leftward shift from baseline (Fig.) , reflecting the pain decrease experienced by the plurality of the patients (99 of 112 or 88.4%; Table 2 ). The median and mean decreases in pain score were 2 and 2.4. No patient reported increased pain immediately after treatment, and for practically every baseline pain score, the majority (78%-100%) reported a decrease in pain (Table 2) . It is interesting to note that the decreases were even more marked for higher baseline pain scores (86%-100% for scores ≥5).
At posttreatment day 1, 80.7% (88 of 109) of the patients continued experiencing decreased pain, whereas 52.4% (55 of 105) and 51% (50 of 98) reported a sustained decrease in pain at days 7 and 30, respectively (Table 2 ). After posttreatment day 1, when the pain score distribution was relatively flat, the score displayed an increasingly rightward shift (Fig.) , reflecting that Federman et al • Battlefield Acupuncture Group Visits the treatment effect was "wearing off " and thus resulting in increases in both the median score and the interquartile range (Table 1) . On day 30, however, the proportion reporting an increase in pain from baseline was only 14 of 90 (15.6%), essentially unchanged from the 16 of 96 (16.7%) on day 7 (Table 2) . Of note, not even one patient with baseline pain scores of 8 and 9 reported worsening of the pain, even at day 30 (Table 2) . Overall, there was a sustained median decrease in pain score for the duration of this study (Table 1) , with many more patients experiencing a decrease in pain than an increase for all baseline pain scores and at all days measured (Table 2) . Moreover, the pain score distribution at each posttreatment time point was significantly different from that at baseline (all P < 0.0001; Table 1 ).
Results of the subgroup analysis to determine whether the baseline pain score affected the durability of BFA treatment showed that although a majority of patients (nearly 9 of 10; Table 2 ) benefited from pain decrease immediately after treatment, the decrease was more sustained in patients with higher baseline scores, suggesting that patients with greater baseline pain scores may experience a more prolonged benefit from BFA. For example, among all patients with a baseline pain score ≥6 (moderate to severe pain), 47 of 77 (61%) and 42 of 73 (58%) patients reported decreased pain on days 7 and 30 ( Table 2 ). The corresponding proportions for pain scores ≤5 were 8 of 28 (28.6%) and 8 of 25 (32.0%) on days 7 and 30.
A large proportion (98 of 112 or 88%) of the patients who signed up for BFA treatment completed the study (Table 1) . Also, the number of patients not reporting pain scores did not vary much from the baseline pain score ( Table 2) .
The common adverse events were mild, including transient euphoria lasting up to 15 minutes in 6 patients, 2 reports of nausea, and 2 cases of dyspigmentation that resolved, but there was no serious adverse event, such as infection.
Discussion
Pain is associated with decreased quality of life and is one of the most common presenting symptoms in primary care. It remains poorly understood and the traditional, pharmacologic-based treatment approach is associated with serious complications. An effective, nonpharmacologic option for pain relief should therefore be a priority. Our results indicate that BFA performed as part of a shared medical appointment is an effective and efficient way to lower self-reported pain scores, with durability of relief in a sizeable proportion of patients.
The strengths of our study include that our results were obtained in a real-world clinical practice in patients with a broad spectrum of chronic conditions. Our pragmatic approach offers greater generalizability than using stricter inclusion or exclusion criteria. In addition, the number of patients not reporting pain scores was reasonably independent of baseline pain score, indicating minimal reporting bias.
There are several limitations to our study. Patients were not randomized to the intervention and it is likely that those who received the treatment were favorably disposed toward acupuncture and therefore more likely to experience a positive result. Because of the nature of the treatment, a randomized doubleblind placebo-controlled study of BFA is difficult to perform. Moreover, sham acupuncture may actually cause analgesia. 7, 26 Another limitation to our study was that it did not have a control population of veterans. Furthermore, although we asked patients to avoid new therapies for the 30-day period after BFA, it is possible that changes in treatment occurred. Finally, the natural healing process could have contributed to some of the intermediate-and long-term improvement, but it would not account for the high rate of improvement seen immediately after treatment. Also, the large proportion of patients who completed the study may have indicated that they perceived BFA to be effective.
Our preliminary results show that BFA performed in a group setting at a VA primary care clinic is highly effective for short-and intermediate-term pain reduction and may continue to provide relief over the longer term, albeit in a smaller subset of patients-those who experienced the most intense pretreatment pain. The finding that more than half of the patients benefited even 30 days after treatment is encouraging, as was the absence of serious adverse events. Moreover, almost 90% of the patients completed the study, indicating that the treatment was well received. Compared with narcotics, the cost of BFA treatment is low, with 10 needles costing approximately US$5. 7, 12, 14 This simple protocol, which can be learned in a single 4-hour session, is inexpensive to teach, takes only a few minutes to perform, and requires little follow-up. 7, 11, 12, 14, 21 Conclusions BFA, a low-risk, inexpensive, nonpharmacologic procedure has the potential to reduce pain, especially in those with high pain scores. A more rigorous investigation of the long-term effects of BFA treatment appears warranted, to both assess efficacy and facilitate development of an effective treatment protocol.
